Thursday, 12 June 2014

Endovascular Abdominal Aortic Aneurysm Repair Devices Market – Research Report, 2013 – 2019

Aortic Aneurysm is a widening of the aorta (body’s largest artery) at a certain spot in the wall of aorta and can potentially rupture the artery due to blood pressure and other factors such as xxx. This can lead to massive internal bleeding if not rapidly treated by experienced emergency medical team. As aorta carries blood from heart and runs through chest and abdomen, the aneurysms are possibly observed at these locations and termed as abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA). Endovascular aneurysm repair (EVAR) is performed to correct these aneurysms in which the weak spot is sealed tightly with an endovascular stent graft. Devices for repairing abdominal aortic aneurysms is known are known as abdominal aortic aneurysm repair devices or more commonly as endovascular stent grafts.

Globally, the physicians are preferring endovascular repair of abdominal aortic aneurysms (AAA) over the open surgical repair because of minimal invasive procedure and faster recovery. Presently, more than 60 percent of AAA repairs are performed using EVAR rather than open surgery which reflects the increasing adoption of endovascular stent grafts systems.
The surgical procedure for treating AAA was first performed in 1991 and since then it has become very popular among surgeons all over the world. The popularity of this procedure is attributed to advances in the stent-graft design happened over several years. Furthermore the devices used for these procedures have undergone drastic changes to suit specific anatomical parts which have helped increasing the number of AAA endovascular stent graft procedures and eventually the demand for these devices.

These devices offer several advantages such as minimal stay at hospitals (24 o 48 hours) and patients can return to normal activities sooner compared to open surgical repairs. These advantages improve the quality of life of an individual as well save huge hospitalization charges and are therefore the biggest driving factor for the growth of this market. Although, these devices have benefits over surgical repair, the technology today still has certain drawbacks such as problem of endoleaks (blood leaks from the treated segment), need of regular surveillance, and graft movement or integrity issues. The global endovascular abdominal aortic aneurysm repair devices market is expected to expand as the ongoing research find solutions to these restraining factors.

Some of the FDA approved devices for endovascular aneurysm repair include, AneuRx AAA stent-graft system (Medtronic, Inc.), GORE EXCLUDER (W. L. Gore & Associates, Inc.), Zenith Flex (Cook Medical, Inc.), and Talent Abdominal Stent Graft (Medtronic, Inc.). Other FDA approved device in the market includes AFX Endovascular AAA System by Endologix, Inc. (in the U.S.) and IntuiTrak Powerlink System (outside the U.S.). These devices differ with respect to usage of stent material and graft material. For instance, Medtronic and W. L. Gore & Associates use nitinol for stents while Cook Medical, Inc. uses stainless steel for stents. On the other hand graft material is either made up of woven polyster or expanded polytetrafluoroethylene (ePFTE).

Some of the companies operating in the global endovascular abdominal aortic aneurysm repair devices market include Bolton Medical, Inc., Cardiatis S.A., Cordis Corporation, Cook Medical Inc., LeMaitre Vascular Inc., JOTEC GmbH, TriVascular, Inc., Terumo Cardiovascular Systems Corporation, TriVascular, Inc., Lombard Medical Technologies plc, Medtronic, Inc., Endologix Inc., Nano Endoluminal, Vascutek Ltd., Aptus Endosystems Inc., and W. L. Gore & Associates.

Early toxicity testing market can be segmented in various categories such as on the basis of regional geography, approach of technique and according to market share by major companies. According to technical approach early toxicity testing market is segmented in in vivo, in vitro and in silico, among all these in vivo market contributing highest followed by in vitro and in silico. Pharmaceutical companies, chemical companies and companies related to food products are main customers for early toxicity detection testing players.

Some of the market players in this industry segment are Accelrys, BD Biosciences, Beckman Coulter, Inc., Charles River Laboratories, Gene Logic, Invitrogen, Covance, IDBS, Thermo Fisher.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America
  • Asia Pacific
  • Europe
  • Rest of the World
This report provides comprehensive analysis of
  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Upcoming Report :- 

About Us:-
Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

Contact Us :-
Sheela AK
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +1-518-618-1030

Browse Market Research Report:-


Post a Comment